By InvitationNot Applicable

Clinical Cohort Construction Program of Peking University Third Hospital

China500 participantsStarted 2014-01-01

Plain-language summary

Cardiac arrest is one of the leading life-threatening emergencies, with approximately 540,000 cases occurring annually in China. Among patients who experience cardiac arrest, active cardiopulmonary resuscitation can achieve return of spontaneous circulation in 40% of cases; however, only 1-2% ultimately survive with favorable neurological outcomes. The primary contributor to mortality and morbidity is post-cardiac arrest syndrome (PCAS). PCAS represents a distinct pathophysiological process resulting from systemic ischemia/reperfusion injury, involving multiple systems and organs, and thus requires comprehensive, systematic evaluation. At present, numerous challenges remain in the field of PCAS, including the optimal targeted temperature, additional interventions that may improve neurological prognosis, post-resuscitation myocardial dysfunction and its protective strategies, characteristics and management of dysfunction in other organs, and accurate neurological prognostication after resuscitation. Therefore, in-depth research on PCAS is urgently needed to improve outcomes in cardiac arrest survivors. This study is initiated by the Department of Emergency Medicine, Peking University Third Hospital, and involves a total of six tertiary hospitals across China, constituting a multicenter investigation. The study aims to explore the effects of different targeted temperature management strategies on mortality and neurological outcomes, and to actively investigate other interventions that may ameliorate post-resuscitation brain injury, cardiac injury, and microcirculatory dysfunction, thereby reducing mortality and improving neurological prognosis in cardiac arrest patients. Furthermore, we aim to develop a neurological prediction model for cardiac arrest patients to enable accurate prognostication of neurological outcomes, which will assist emergency physicians in providing precise prognostic information to families and facilitate shared decision-making regarding subsequent treatment plans.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patients who have achieved return of spontaneous circulation (ROSC) after cardiac arrest;
. With accessible intravenous or intraosseous vascular access;
. Clinical manifestations meeting any one of the following criteria: presenting with post-resuscitation brain injury, post-resuscitation cardiac dysfunction, manifestations of systemic ischemia-reperfusion injury, or other ongoing deteriorating pathological changes.

Exclusion criteria

. Patients who have not achieved return of spontaneous circulation (ROSC) after cardiac arrest;
. Patients who have declined cardiopulmonary resuscitation (CPR) (or whose legally authorized representative has refused CPR).

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Whether death has occurred

Timeframe: 1 year

Trial details

NCT IDNCT07762144

SponsorPeking University Third Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2030-12-31

View on ClinicalTrials.gov More Post-Cardiac Arrest Syndrome trials